Edgewise Therapeutics Inc
EWTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.96B
Close$
$0.56
98.5% downside
Current Fair Value
98.5% downsideOvervalued by 98.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.96 Billion |
|---|---|
| Enterprise Value | $3.93 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.63 |
| Beta | 0.3 |
| Outstanding Shares | 107,116,709 |
Return
| Return on Equity | -35.69% |
|---|---|
| Return on Assets | -33.94% |
| Return on Invested Capital | -39.07% |
Valuation & Multiples
| P/E Ratio | -22.17 |
|---|---|
| PEG | -110.13 |
| Price to Sales | - |
| Price to Book Ratio | 9.13 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -20.28 |
| Enterprise Value to Net Income | -23 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.50
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.50
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5944▼ 36.61% |
|---|---|
| Total Calls | 552,839▲ 15.66% |
| Total Puts | 328,600▼ 28.43% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 115.16%▼ 0.32% |
|---|---|
| Total Invested | $3.72B▲ 23.12% |
| Investors Holding | 225▲ 13.00% |
ESG Score
No data
About Edgewise Therapeutics Inc
19 employeesEdgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need....